165 related articles for article (PubMed ID: 38464204)
1. PROTAC-mediated dual degradation of BCL-xL and BCL-2 is a highly effective therapeutic strategy in small-cell lung cancer.
Khan S; Cao L; Wiegand J; Zhang P; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
bioRxiv; 2024 Mar; ():. PubMed ID: 38464204
[TBL] [Abstract][Full Text] [Related]
2. PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer.
Khan S; Cao L; Wiegand J; Zhang P; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
Cells; 2024 Mar; 13(6):. PubMed ID: 38534371
[TBL] [Abstract][Full Text] [Related]
3. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas.
He Y; Koch R; Budamagunta V; Zhang P; Zhang X; Khan S; Thummuri D; Ortiz YT; Zhang X; Lv D; Wiegand JS; Li W; Palmer AC; Zheng G; Weinstock DM; Zhou D
J Hematol Oncol; 2020 Jul; 13(1):95. PubMed ID: 32677976
[TBL] [Abstract][Full Text] [Related]
4. Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells.
Jia Y; Han L; Ramage CL; Wang Z; Weng CC; Yang L; Colla S; Ma H; Zhang W; Andreeff M; Daver N; Jain N; Pemmaraju N; Bhalla K; Mustjoki S; Zhang P; Zheng G; Zhou D; Zhang Q; Konopleva M
Haematologica; 2023 Oct; 108(10):2626-2638. PubMed ID: 37078252
[TBL] [Abstract][Full Text] [Related]
5. A selective BCL-X
Khan S; Zhang X; Lv D; Zhang Q; He Y; Zhang P; Liu X; Thummuri D; Yuan Y; Wiegand JS; Pei J; Zhang W; Sharma A; McCurdy CR; Kuruvilla VM; Baran N; Ferrando AA; Kim YM; Rogojina A; Houghton PJ; Huang G; Hromas R; Konopleva M; Zheng G; Zhou D
Nat Med; 2019 Dec; 25(12):1938-1947. PubMed ID: 31792461
[TBL] [Abstract][Full Text] [Related]
6. Co-targeting BCL-X
Khan S; Kellish P; Connis N; Thummuri D; Wiegand J; Zhang P; Zhang X; Budamagunta V; Hua N; Yang Y; De U; Jin L; Zhang W; Zheng G; Hromas R; Hann C; Zajac-Kaye M; Kaye FJ; Zhou D
Cell Death Discov; 2023 Jan; 9(1):1. PubMed ID: 36588105
[TBL] [Abstract][Full Text] [Related]
7. Strategies to Reduce the On-Target Platelet Toxicity of Bcl-x
Negi A; Voisin-Chiret AS
Chembiochem; 2022 Jun; 23(12):e202100689. PubMed ID: 35263486
[TBL] [Abstract][Full Text] [Related]
8. Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL.
Nayak D; Lv D; Yuan Y; Zhang P; Hu W; Nayak A; Ruben EA; Lv Z; Sung P; Hromas R; Zheng G; Zhou D; Olsen SK
Nat Commun; 2024 Mar; 15(1):2743. PubMed ID: 38548768
[TBL] [Abstract][Full Text] [Related]
9. BCL-X
Khan S; Wiegand J; Zhang P; Hu W; Thummuri D; Budamagunta V; Hua N; Jin L; Allegra CJ; Kopetz SE; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
J Hematol Oncol; 2022 Mar; 15(1):23. PubMed ID: 35260176
[TBL] [Abstract][Full Text] [Related]
10. Resistance to the BCL-XL degrader DT2216 in T-cell acute lymphoblastic leukemia is rare and correlates with decreased BCL-XL proteolysis.
Jaiswal A; Jaiswal A; Williamson EA; Gelfond J; Zheng G; Zhou D; Hromas R
Cancer Chemother Pharmacol; 2023 Jan; 91(1):89-95. PubMed ID: 36346454
[TBL] [Abstract][Full Text] [Related]
11. Anti-apoptotic protein BCL-XL as a therapeutic vulnerability in gastric cancer.
Wei Y; Zhang L; Wang C; Li Z; Luo M; Xie G; Yang X; Li M; Ren S; Zhao D; Gao R; Gong JN
Animal Model Exp Med; 2023 Jun; 6(3):245-254. PubMed ID: 37271936
[TBL] [Abstract][Full Text] [Related]
12. Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity.
He Y; Zhang X; Chang J; Kim HN; Zhang P; Wang Y; Khan S; Liu X; Zhang X; Lv D; Song L; Li W; Thummuri D; Yuan Y; Wiegand JS; Ortiz YT; Budamagunta V; Elisseeff JH; Campisi J; Almeida M; Zheng G; Zhou D
Nat Commun; 2020 Apr; 11(1):1996. PubMed ID: 32332723
[TBL] [Abstract][Full Text] [Related]
13. Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-X
Thummuri D; Khan S; Underwood PW; Zhang P; Wiegand J; Zhang X; Budamagunta V; Sobh A; Tagmount A; Loguinov A; Riner AN; Akki AS; Williamson E; Hromas R; Vulpe CD; Zheng G; Trevino JG; Zhou D
Mol Cancer Ther; 2022 Jan; 21(1):184-192. PubMed ID: 34667112
[TBL] [Abstract][Full Text] [Related]
14. AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x
Balachander SB; Criscione SW; Byth KF; Cidado J; Adam A; Lewis P; Macintyre T; Wen S; Lawson D; Burke K; Lubinski T; Tyner JW; Kurtz SE; McWeeney SK; Varnes J; Diebold RB; Gero T; Ioannidis S; Hennessy EJ; McCoull W; Saeh JC; Tabatabai A; Tavana O; Su N; Schuller A; Garnett MJ; Jaaks P; Coker EA; Gregory GP; Newbold A; Johnstone RW; Gangl E; Wild M; Zinda M; Secrist JP; Davies BR; Fawell SE; Gibbons FD
Clin Cancer Res; 2020 Dec; 26(24):6535-6549. PubMed ID: 32988967
[TBL] [Abstract][Full Text] [Related]
15. PROTACs are effective in addressing the platelet toxicity associated with BCL-X
Zhang P; Zhang X; Liu X; Khan S; Zhou D; Zheng G
Explor Target Antitumor Ther; 2020; 1(4):259-272. PubMed ID: 34296214
[TBL] [Abstract][Full Text] [Related]
16. CBFA2T3::GLIS2 pediatric acute megakaryoblastic leukemia is sensitive to BCL-XL inhibition by navitoclax and DT2216.
Gress V; Roussy M; Boulianne L; Bilodeau M; Cardin S; El-Hachem N; Lisi V; Khakipoor B; Rouette A; Farah A; Théret L; Aubert L; Fatima F; Audemard É; Thibault P; Bonneil É; Chagraoui J; Laramée L; Gendron P; Jouan L; Jammali S; Paré B; Simpson SM; Tran TH; Duval M; Teira P; Bittencourt H; Santiago R; Barabé F; Sauvageau G; Smith MA; Hébert J; Roux PP; Gruber TA; Lavallée VP; Wilhelm BT; Cellot S
Blood Adv; 2024 Jan; 8(1):112-129. PubMed ID: 37729615
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a Novel BCL-X
Pal P; Thummuri D; Lv D; Liu X; Zhang P; Hu W; Poddar SK; Hua N; Khan S; Yuan Y; Zhang X; Zhou D; Zheng G
J Med Chem; 2021 Oct; 64(19):14230-14246. PubMed ID: 34533954
[TBL] [Abstract][Full Text] [Related]
18. Bcl-2/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in pancreatic cancer cells via inhibition of Bcl-xL but not Bcl-2.
Morimoto Y; Takada K; Takeuchi O; Watanabe K; Hirohara M; Hamamoto T; Masuda Y
Mol Cell Biochem; 2020 Sep; 472(1-2):187-198. PubMed ID: 32567031
[TBL] [Abstract][Full Text] [Related]
19. Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity.
Lv D; Pal P; Liu X; Jia Y; Thummuri D; Zhang P; Hu W; Pei J; Zhang Q; Zhou S; Khan S; Zhang X; Hua N; Yang Q; Arango S; Zhang W; Nayak D; Olsen SK; Weintraub ST; Hromas R; Konopleva M; Yuan Y; Zheng G; Zhou D
Nat Commun; 2021 Nov; 12(1):6896. PubMed ID: 34824248
[TBL] [Abstract][Full Text] [Related]
20. Discovery of PROTAC BCL-X
Zhang X; Thummuri D; Liu X; Hu W; Zhang P; Khan S; Yuan Y; Zhou D; Zheng G
Eur J Med Chem; 2020 Apr; 192():112186. PubMed ID: 32145645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]